| 应用 | 9,10-Dihydroanthracene(DHA) has been used in a study to assess the hydrogen abstraction capability of valence-delocalized iron complex with DHA in MeCN. |
| 产品介绍 | 9,10-Dihydroanthracene causes the transfer hydrogenation of C60 and C70 in the presence of [7H]benzanthrene catalyst. It was oxidatively aromatized to the corresponding anthracene in the presence of molecular oxygen as an oxidant and activated carbon as a promoter in xylene. |
| 别名 | ; |
9,10-二氢蒽
9,10-Dihydroanthracene （订货以英文为准）
编号：D155012
CAS号：613-31-0
分子式：C14H12
分子量：180.24
| 产品名称 | 9,10-Dihydroanthracene |
| 中文名称 | 9,10-二氢蒽 |
| CAS号 | 613-31-0 |
| 分子式（M.F.） | C14H12 |
| 分子量（M.W.） | 180.24 |
| Reaxys-RN | 2937659 |
技术规格
| Background: | Transcriptional activator, probably constitutive, which binds to the cAMP-responsive element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Interaction with JUN redirects JUN to bind to CRES preferentially over the 12-O-tetradecanoylphorbol-13-acetate response elements (TRES) as part of an ATF2-c-Jun complex. |
| Applications: | WB, IHC |
| Name of antibody: | ATF2 (Phospho-Ser112 or 94) |
| Immunogen: | Synthetic peptide of human ATF2 (Phospho-Ser112 or 94) |
| Full name: | activating transcription factor 2 (Phospho-Ser112 or 94) |
| Synonyms： | HB16; CREB2; TREB7; CRE-BP1 |
| SwissProt: | P15336 |
| IHC positive control: | Human breast carcinoma |
| IHC Recommend dilution: | 50-100 |
| WB Predicted band size: | 65-75 kDa |
| WB Positive control: | HUVEC cells treated with Anisomycin |
| WB Recommended dilution: | 500-1000 |
搜索质检报告(COA)
搜索MSDS
相关产品
党沛 
